NYSE:BMYPharmaceuticals
FDA Iberdomide Review Puts Focus On Bristol-Myers Squibb Valuation Gap
The FDA has accepted Bristol-Myers Squibb’s New Drug Application for iberdomide in combination with other therapies for relapsed or refractory multiple myeloma.
The filing has received both Breakthrough Therapy Designation and Priority Review from the FDA.
The decision focuses on patients with hard to treat multiple myeloma who have limited options after prior therapies.
Bristol-Myers Squibb (NYSE: BMY) now has iberdomide under Priority Review at a time when its shares trade around $60.66...